Use of F-652 in Patients With Alcoholic Hepatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Alcoholic Hepatitis
Interventions
DRUG

F-652

Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Indiana University

OTHER

collaborator

Virginia Commonwealth University

OTHER

collaborator

Hennepin County Medical Center, Minneapolis

OTHER

lead

Mayo Clinic

OTHER